Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Down 14.7% in February

Shattuck Labs, Inc. (NASDAQ:STTK) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 1,921,827 shares, a decrease of 14.7% from the January 29th total of 2,251,778 shares. Approximately 3.5% of the shares of the company are sold short. Based on an average trading volume of 334,601 shares, the days-to-cover ratio is presently 5.7 days. Based on an average trading volume of 334,601 shares, the days-to-cover ratio is presently 5.7 days. Approximately 3.5% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on STTK. Citigroup boosted their price target on Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Monday, December 1st. Finally, Piper Sandler began coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price target on the stock. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.20.

Shattuck Labs Price Performance

STTK stock opened at $4.23 on Wednesday. The business’s 50-day moving average price is $4.05 and its 200-day moving average price is $2.77. The stock has a market cap of $267.67 million, a P/E ratio of -4.15 and a beta of 1.55. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $4.89.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. purchased a new stake in Shattuck Labs in the 4th quarter worth $4,945,000. Invesco Ltd. purchased a new stake in shares of Shattuck Labs during the fourth quarter worth about $103,000. EP Wealth Advisors LLC purchased a new stake in shares of Shattuck Labs during the fourth quarter worth about $150,000. Sphera Funds Management LTD. bought a new stake in Shattuck Labs during the 4th quarter valued at approximately $713,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Shattuck Labs in the 4th quarter worth approximately $7,031,000. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.